# MOH earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/MOH) · [Earnings tab](https://www.lopjlb.com/stock/MOH?tab=earnings)

Updated: 2026-10-05T08:20:03

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of earnings calls, Molina’s outlook shifted from a confident reaffirmation of premium and EPS targets in late 2024 to a sharp EPS downgrade in 2025 amid heightened medical cost and Medicaid rate pressures. By 2026 the company restored its FY guidance and even nudged EPS higher, citing stable Medicaid margins and strong cash generation, yet it flagged persistent uncertainties around Medicaid rate updates, Marketplace regulatory changes, and rising enrollment attrition. The tone moved from modest optimism (0.60) to low confidence (0.20) and back toward moderate optimism (0.30) as the firm balanced margin compression with capital returns and opportunistic acquisitions. Core themes such as Medicaid cost pressure, medical cost trends, and Marketplace utilization pressures remained recurring, while new concerns like subsidy expiration and state work‑community rules emerged later. Milestones progressed from early contract wins and acquisitions to delivered share repurchases and dual‑product transitions, with several initiatives still open. Overall, the narrative reflects a company navigating tightening margins and enrollment headwinds while leveraging capital strength to sustain growth prospects.

## Latest CallCard · Q2

Molina Q2 2026: EPS $1.51 on $10.2B premium; raised 2026 EPS guidance to $5.25; Medicaid stable, Medicare duals strong, Marketplace challenged; 2027 premium ~$46.5B, EPS building blocks >$10; Florida CMS contract $1.50 drag in 2026; confident in 2029 $25 EPS target.

**Guidance:** raised — Full-year 2026 adjusted EPS guidance raised to at least $5.25 from $5.00; premium revenue unchanged at ~$42B; Medicaid MCR unchanged at 92.9%; Medicare MCR improved to 92.2%; Marketplace MCR increased to 90% with EPS loss of $0.75.

**Tone:** mgmt 0.3 · Q&A pressure 0.6 · divergence 0.2

Management highlighted solid Medicaid performance, strong Medicare duals results, raised EPS guidance, and expressed confidence in 2027 building blocks and 2029 targets while acknowledging Marketplace headwinds.

### Demand visibility

Medicaid enrollment declines projected at 2-3% annually for 3 years; Marketplace footprint shrinking to ~6 states; Medicare duals expanding via RFP wins.

Management expects Medicaid membership to decline 2-3% per year over 3 years (8-9% cumulative) with minor acuity shift; Marketplace membership concentrated in ~6 states with $1B premium reduction; Medicare duals benefiting from RFP wins and MMP conversions.

### Margins / costs

Medicaid MCR stable at 92.7% Q2, full-year 92.9%; Medicare duals MCR 90.7% Q2, full-year 92.2%; Marketplace MCR 88.9% Q2, full-year 90%; medical cost trend Medicaid 5%, Medicare duals 4%.

Medicaid medical cost trend stable at 5% with high-cost categories plateauing; Medicare duals trend improved to 4% from 6% guided across inpatient, pharmacy, outpatient, professional, LTSS; Marketplace impacted by prior-year risk adjustment true-ups and program integrity items ($1.00 EPS) and current-year unfavorable acuity mix ($1.00 EPS); G&A ratio 6.5% Q2, guided 6.4% full year with fixed/variable split.

### Capital allocation

Strong capital position with $290M parent cash, targeting $

## Quarter one-liners

- **2026 Q2:** Molina Q2 2026: EPS $1.51 on $10.2B premium; raised 2026 EPS guidance to $5.25; Medicaid stable, Medicare duals strong, Marketplace challenged; 2027 premium ~$46.5B, EPS building blocks >$10; Florida CMS contract $1.50 drag in 2026; confident in 2029 $25 EPS target.
- **2026 Q1:** Molina reaffirmed FY2026 guidance of $42B premium revenue and $5 EPS, noted higher Medicaid attrition (6% vs 2%) offset by Marketplace, highlighted low/no utilizers at historic lows and confidence in a ~5% medical cost trend.
- **2025 Q4:** —
- **2025 Q3:** Molina cut FY2025 EPS guidance to $14, citing higher medical cost trends and Marketplace pressure, but sees upside from Medicaid rate advocacy, new contracts and opportunistic M&A.
- **2025 Q2:** —
- **2025 Q1:** —
- **2024 Q4:** —
- **2024 Q3:** Molina reaffirmed $38B premium revenue and $23.50 EPS guidance, noting Medicaid cost pressure, rate updates and new state contracts as drivers of near‑term uncertainty but long‑term growth confidence.

## Theme arcs

- **EPS guidance trajectory** (deteriorating): Guidance fell from $23.50 EPS (2024) to $14 (2025) then modestly recovered to $5‑$5.25 (2026)
- **Medicaid rate and cost pressure** (stable): Rate uncertainty and underfunding cited in 2024, 2025 and 2026 calls
- **Medical cost trend volatility** (deteriorating): Consistent pressure from LTSS, pharmacy and high‑cost drugs; 2026 notes possible volatility
- **Marketplace dynamics** (deteriorating): Utilization pressure, subsidy uncertainty and regulatory risk highlighted in 2025‑2026
- **Enrollment attrition** (deteriorating): Higher Medicaid attrition noted in 2025 and 2026
- **Capital strength and returns** (improving): Share buybacks, strong cash flow and low‑40s debt‑to‑capital ratio emphasized in 2024‑2026
- **Margin compression (MCR)** (deteriorating): MCR pressures and corridor cushion depletion discussed in 2024 and 2025

## Fear persistence

- **Medicaid rate and cost pressure** [recurring]: Rate uncertainty (2024), underfunding (2025), off‑cycle updates (2026)
- **Medical cost trend pressure** [recurring]: Elevated costs noted in 2024‑2025, volatility flagged in 2026
- **Marketplace utilization and regulatory pressure** [recurring]: Utilization pressure (2025), subsidy/regulatory uncertainty (2025‑2026)
- **Enrollment decline/attrition** [recurring]: Enrollment decline (2025) and higher attrition (2026)
- **Corridor depletion** [resolved]: Only mentioned in 2024 Q3
- **Subsidy expiration uncertainty** [new]: Raised in 2025 Q3, not repeated
- **State work/community engagement requirements** [new]: Introduced in 2026 Q1

## Guidance path

2024 Q3:maintained → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:lowered → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:raised

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/MOH`